Objective Chronic HCV infection is characterised by innate immune activation with increased interferonstimulated genes (ISG) expression and by an altered phenotype of interferon-responsive natural killer (NK) cells. Here, we asked whether a rapid reduction in viremia by daclatasvir (DCV) and asunaprevir (ASV) improves the response to pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy. Design Twenty-two HCV-infected non-responders to previous PegIFN/RBV therapy were studied for IFNresponsiveness of NK cells during quadruple (QUAD) therapy with DCV, ASV, PegIFN and RBV. A direct comparison of early NK cell responses in PegIFN/RBV therapy and QUAD therapy was performed for seven patients using paired cryopreserved peripheral blood mononuclear cells (PBMC) from both treatment courses. As a validation cohort, nine DCV/ASV-treated patients were studied for their NK cell response to in vitro stimulation with IFNα. Results The 24 h virological response to QUAD therapy correlated with an increase in signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1 ( pSTAT1) and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) expression in NK cells, and the STAT1/pSTAT1/TRAIL induction was greater during QUAD therapy than during previous PegIFN/RBV therapy. Successful QUAD therapy as well as successful IFN-free DCV/ASV regimen resulted in an improved functional NK cell response (degranulation and TRAIL expression) to in vitro stimulation with IFNα.
INTRODUCTION
The introduction of potent direct acting antivirals (DAAs) has significantly improved the treatment response of patients with chronic HCV infection. However, at present, these interferon (IFN)-free treatment regimens are not available for most
Significance of this study
What is already known on this subject?
▸ HCV induces endogenous type I and III interferons (IFNs) that stimulate high expression levels of interferon-induced genes and activate IFN-sensitive innate immune cells such as natural killer (NK) cells. ▸ The degree of innate immune activation and the patient's IFN-λ genotype predict the response to IFN-based therapy. ▸ Due to the limited availability and high costs of direct acting antivirals (DAAs), the WHO has estimated in its treatment guidelines that IFN-based therapy will be the sole available therapy in low-income and middle-income countries for the next several years. ▸ In addition, IFN remains important in combination with DAAs in difficult-to-cure patients, such as patients with HCV genotype 3 infection.
What are the new findings?
▸ Interferon-responsiveness is not solely genetically determined but can be improved by inhibiting viral replication and reducing the virus-induced activation of the innate immune response. ▸ HCV genotype 1a-infected non-responders to past pegylated IFN (PegIFN)/ribavirin (RBV) responded to combination therapy with PegIFN, RBV, daclatasvir (DCV) and asunaprevir (ASV). ▸ The rapid DCV/ASV-induced reduction in viremia increased the innate response to PegIFN as evidenced by greater induction of signal transducer and activator of transcription 1 (STAT1), phosphorylated STAT1 and tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) than during past PegIFN/RBV therapy. A response to quadruple therapy was associated with improved NK cell degranulation upon in vitro stimulation with IFNα. ▸ Rapid reduction of viremia by an IFN-free DCV/ ASV regimen also improved IFN-responsiveness of NK cells, as shown by in vitro stimulation with IFNα.
patients worldwide, partly due to the high costs. In its 2014 guidelines on screening, care and treatment of patients with HCV infection in low-income and middle-income countries, 1 the WHO has provided recommendations for all currently licensed treatments for HCV infection, that is, for IFN-based regimens ( pegylated IFN (PegIFN)/ribavirin (RBV)), combination regimens of PegIFN/RBV and DAAs, and IFN-free DAA regimens. The WHO conceded in its report that 'it is likely that in many countries PegIFN and RBV will be the only available medicines for the next several years'. 1 PegIFN also remains important for the treatment of patients with HCV genotype 3 infection, because the addition of PegIFN to a sofosbuvir (SOF)/RBV regimen increased the sustained virological response (SVR) rate in patients with cirrhosis from 47% to 83% and in those without cirrhosis from 76% to 94%. 2 These data are even more remarkable when one considers the length of treatment. The length of the PegIFN/SOF/RBV regimen was 12 weeks, whereas the length of the SOF/RBV regimen was 16 weeks. Even an extension of the SOF/RBV regimen to 24 weeks did not yield the SVR rates of the 12-week PegIFN/SOF/RBV regimen. 2 Responsiveness to IFN-based therapy is determined by the pre-treatment activation state of the innate immune response. 3 HCV infection is known to induce endogenous type I and III IFNs, which increase the expression of IFN-stimulated genes (ISGs) 3 and activate IFN-sensitive innate immune cells such as natural killer (NK) cells. [4] [5] [6] Chronically HCV-infected patients with a highly activated innate immune state do not respond well to IFN-based therapy compared with patients with weaker activation. 3 Likewise, a strong activation of NK cells in chronic HCV infection prior to treatment has been associated with nonresponse to IFN-based therapy. [7] [8] [9] The level of innate immune activation is greater, thus the responsiveness to exogenous IFN is lower, in the presence than in the absence of the unfavourable IL28B variants rs12979860-T 10 11 and rs368234815 ΔG. 12 At present, it is not known whether the IFN-responsiveness of individual patients can be improved.
Here we asked whether the rapid decrease in HCV titre by DAAs reduces the activation state of the innate immune system and thereby improves the responsiveness to PegIFN/RBV. For this purpose, we compared IFN-responsiveness in a cohort of patients with HCV genotype 1a infection with unfavourable IL28B genotype during a failed course of PegIFN/RBV treatment, and during a subsequent successful combination therapy of PegIFN/RBV and the DAAs daclatasvir (DCV) and asunaprevir (ASV) (hereafter called QUAD therapy). Patients with HCV genotype 1a infection are an ideal cohort to study the synergistic effect of DCV/ASV and PegIFN/RBV in a QUAD regimen because in contrast to patients with HCV genotype 1b infection, [13] [14] [15] [16] patients with HCV genotype 1a infection have a very low SVR rate when treated with DCV/ASV alone and require the addition of PegIFN and RBV. 17 18 A similar synergistic effect is observed when other DAAs are combined with PegIFN/RBV for treatment of patients with HCV genotype 1a infection. 19 As a readout for IFN-responsiveness, we studied NK cells, because they express the IFNα/β receptor and are highly sensitive to type I IFN. 20 We and others have previously shown quantifiable changes in the phenotype and function of NK cells in response to both endogenous, HCV-induced IFN 4 and exogenous, therapeutically administered PegIFN. 6 21 Specifically, IFNα induces signal transducer and activator of transcription 1 (STAT1) and phosphorylated STAT1 ( pSTAT1) levels in NK cells 5 6 and enhances NK cell cytotoxicity, as evidenced by increased degranulation and production of the cytotoxic molecule tumour necrosis factor-related apoptosisinducing ligand (TRAIL), which itself is an ISG. 4 21 22 In contrast, pSTAT4 levels and cytokine production decrease upon stimulation with type I IFN. 4 6 22 Based on an analysis of pSTAT1, STAT1 and TRAIL levels in peripheral blood NK cells, we now demonstrate that the rapid reduction in HCV viremia during the first 24 h of successful QUAD therapy improves NK cell responsiveness to PegIFN compared with a previous unsuccessful course of PegIFN/RBV without DAAs. We validate these findings in a separate cohort of patients with HCV genotype 1b infection who were treated with the same DAAs (ie, with DCV/ ASV) without PegIFN/RBV and show that the NK cell response to in vitro stimulation with IFNα improves after the DCV/ ASV-mediated decrease in HCV titre.
These results imply that IFN-responsiveness is not solely genetically determined but that it can be improved by rapidly reducing HCV RNA levels. This may explain the benefit of combining PegIFN with SOF/RBV therapy in difficult-to-cure patient populations as shown in the BOSON study. 2 The results may also provide a rationale for clinical trials of a brief period of DAA therapy followed by PegIFN/RBV therapy to reduce the overall costs of treatment. Finally, improved NK cell responsiveness may be relevant for improved immune surveillance and prevention of viral relapse, which is an interesting area for future research.
MATERIALS AND METHODS Cohorts for NK cell studies
NK cells were studied from 22 HCV genotype 1a-infected nonresponders to previous PegIFN/RBV therapy (table 1) prior to and at day 0 and 1, and week 4 of a 24-week QUAD treatment course with DCV (60 mg, once daily, Bristol-Myers Squibb, New York, New York, USA), ASV (100 mg, twice daily, Bristol-Myers Squibb), PegIFNα-2a (180 μg/week s.c.) and weight-based RBV (1000 mg for <75 kg bodyweight and 1200 mg for ≥75 kg bodyweight p.o. daily; clinicaltrials.gov registration NCT01888900). Nineteen patients were sustained virological responders with no detectable HCV RNA at week 12 post therapy. One patient stopped treatment at week 8 due to IFN intolerance, one patient experienced a virological breakthrough at week 8 and one patient relapsed after the end of treatment. Based on the availability of cryopreserved peripheral blood mononuclear cells (PBMC), seven responders to QUAD therapy were also studied for NK cell responses during a previous course of PegIFN/RBV therapy, to which they were non-responders (clinicaltrials.gov registration NCT00718172). An additional group of nine non-responders to Significance of this study How might it impact on clinical practice in the foreseeable future?
▸ The results may explain the benefit of combining PegIFN with DAA/RBV therapy in some patient cohorts as shown in the BOSON study. ▸ They may also provide a rationale for clinical trials of a brief period of DAA therapy followed by PegIFN/RBV therapy to reduce the overall costs of treatment in low-income and middle-income countries. ▸ The improved NK cell responsiveness may enhance innate immune surveillance, possibly preventing viral breakthrough and relapse. were also studied during a past course with PegIFN/RBV (figure 5). †PegIFN/RBV, combination therapy with pegylated IFN-α and ribavirin. ‡Liver biopsies were performed 1-4 weeks prior to QUAD therapy. Cirrhosis is based on an Ishak fibrosis score of 5-6, absence of cirrhosis is based on an Ishak fibrosis score <5. §SVR, sustained virological response defined as HCV RNA negative at week 12 post treatment. ¶All patients were nonresponders to previous PegIFN/RBV treatment. A null response is defined as a decrease of HCV-RNA titre <2 log10 IU/mL during the first 12 weeks of PegIFN/RBV. **Relapsed one month after end-of-treatment. † †Stopped treatment at week 8 because of IFN intolerance. ‡ ‡Viral breakthrough detected at week 8 of treatment. ALT, alanine aminotransferase; ASV, asunaprevir; DCV, daclatasvir; NK, natural killer; PBMC, peripheral blood mononuclear cells; QUAD, quadruple; SVR, sustained virological response.
past PegIFN/RBV therapy was studied at day 0 and 1, and week 24 of an IFN-free therapy with DCV (60 mg, once daily) and ASV (100 mg, twice daily), which they responded to (clinicaltrials.gov registration NCT01888900). NK cell responses of 15 uninfected subjects were studied as controls. All patients gave written informed consent for research testing under protocols by the institutional review board of National Institute for Diabetes, Digestive and Kidney Diseases (NIDDK)/National Institute for Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The human experimentation guidelines of the US Department of Health and Human Services were followed.
Genotyping
Genomic DNAs were used to identify the single nucleotide polymorphisms (SNPs) associated with rs12979860, 10 11 rs368234815 ( previously designated as ss469415590), 12 and rs117648444.
12 23 SNP analysis of rs12979860 was carried out with primers and probes from Life Technologies (Carlsbad, California, USA) and SNP analysis of rs368234815 was performed as previously reported.
12 SNP analysis of rs117648444 was carried out using forward primer 5 0 GTCCCGCAGG AGGAAGAG3 0 , reverse primer 5 0 GGGCCTCACGGATGGC 3 0 , and the probes 5 0 CGGAGGATCCCTCC (VIC) 3 0 and 5
To validate the primer and probe set for the rs117648444 SNP analysis, the PCR product was subcloned into the PCR4 TOPO vector (Life Technologies) followed by sequencing.
Serological analyses
Serum HCV RNA levels were quantitated using the Cobas TaqMan real-time PCR assay (Roche Diagnostics, Palo Alto, California, USA), with a lower limit of detection of 10 IU/mL and lower limit of quantification of 25-43 IU/mL (figure 1). Serum CXCL10 was quantitated using the ELISA MAX kit (Biolegend, San Diego, California, USA) following the manufacturer's protocol.
Extraction of RNA, synthesis of cDNA and quantitative PCR of CXCL10
Total RNA was isolated from snap-frozen, mechanically homogenised liver biopsies in RNAlater (Life Technologies) using the Picopure RNA Isolation Kit (Life Technologies) with on-column DNase digestion. A complementary DNA (cDNA) equivalent to 1-2 ng total RNA, generated with Superscript III Reverse Transcriptase (Life Technologies), was used to determine CXCL10 messenger RNA (mRNA) levels with predesigned human TaqMan Gene Expression Assay (Life Technologies). The mRNA levels were normalised to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and PSMB4 and presented as 2 ΔCT in figure 1 .
NK cell analysis
PBMCs were separated from heparin-anticoagulated blood on Ficoll Histopaque (Mediatech, Manassas, Virginia, USA) density gradients, washed three times with phosphate-buffered saline (Mediatech) and cryopreserved in 70% fetal bovine serum (FBS, Serum Source International, Charlotte, North Carolina, USA), 20% RPMI1640 (Mediatech) and 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St. Louis, Missouri, USA). Thawed PBMCs were processed and stained as described below prior to analysis on an LSRII flow cytometer using FacsDiva V.6.1.3 (BD Biosciences, San Jose, California, USA) and FlowJo V.8.8.2 software (Tree Star, Ashland, Oregon, USA).
1. TRAIL and STAT1 staining: Three million thawed PBMCs were incubated with or without 300 ng/mL consensus sequence IFNα (IFNα con1; InterMune, Brisbane, California, USA) in 0.5 mL RPMI1640 with 10% FBS, 1% penicillin/streptomycin and 2 mM L-glutamine (Mediatech) for 10 h at 37°C 5% CO 2 (figures 2-4). For staining, the cell suspension was split into two tubes. Cells in the first tube (TRAIL analysis) were stained with ethidium monoazide (EMA) for 10 min on ice followed by staining with anti-CD3-AlexaFluor700, anti-CD19-PeCy5, anti-CD16-V500, anti-CD56-PeCy7 and anti-TRAIL-PE (all from BD Biosciences), and with anti-CD14-PECy5 (AbD, Raleigh, North Carolina, USA) for 25 min at 4°C. Cells in the second tube (STAT1 analysis) were fixed with BD Cytofix buffer for 10 min at 37°C and 5% CO 2 , centrifuged, permeabilised with BD Perm buffer III for 20 min on ice, washed twice and resuspended in BD Phosflow Buffer (all from BD Biosciences). Cells in this tube were stained with anti-CD56-PE (Beckman Coulter, Brea, California, USA), anti-CD3-FITC, anti-CD20-PerCP/Cy5.5 and anti-STAT1-Alexa647 (all from BD Biosciences) for 20 min at room temperature. 2. pSTAT1 staining: Thawed PBMCs (1.5×10 6 ) were rested in 0.5 mL RPMI1640 with 10% FBS, 1% penicillin/ streptomycin and 2 mM L-glutamine (Mediatech) either overnight (figure 2-5) or for 2 h (figure 6) at 37°C, 5% CO 2 prior to stimulation with or without 300 ng/mL IFNα con1 for 5 min at 37°C. Thereafter, cells were fixed and permeabilised following the same procedure as for To assess NK cell degranulation, one million thawed PBMCs were incubated with or without 3 ng/mL IFNα con1 in 1 mL RPMI1640 with 10% FBS, 1% penicillin/streptomycin, 2 mM L-glutamine and anti-CD107-PE (BD Biosciences) for 7 h at 37°C 5% CO 2 . In contrast to previous degranulation experiments 4 cells were not rested overnight, which resulted in a higher baseline expression of CD107a. Cells were stained with EMA for 10 min on ice and with anti-CD3-AlexaFluor700, anti-CD19-PeCy5, anti-CD16-V500, anti-CD56-PeCy7, anti-TRAIL-APC (all from BD Biosciences) and anti-CD14-PECy5 (AbD Serotec) for 25 min at 4°C. 
Statistical analysis
Depending on data distribution based on D'Agostino & Pearson omnibus normality tests, Wilcoxon signed-rank test, MannWhitney test, unpaired t-test and linear regression analysis were performed with GraphPad Prism V.5.0a (GraphPad Software, La Jolla, California, USA). Two-sided p values <0.05 were considered significant. IFN dose-response stimulation curves (nonlinear regression, variable slope) and the corresponding 50% activity concentrations (EC50) were calculated with GraphPad Prism V.6.0 (GraphPad Software).
RESULTS

The rapid decrease in viremia during QUAD therapy is associated with a decrease in intrahepatic inflammation
To answer the question whether a rapid DAA-mediated reduction of HCV viremia improves the innate immune response to IFNα, we studied 22 non-responders to PegIFN/RBV during a subsequent course of QUAD therapy. The patient characteristics are described in table 1. Of note, 19/22 patients had the unfavourable rs12979860-T and rs368234815-ΔG/rs117648444-G genetic variants associated with non-responsiveness to IFN-based therapy. All 22 patients experienced a rapid decline in HCV RNA levels within 24 h of QUAD therapy and had undetectable viremia by week 4 of QUAD therapy ( figure 1A ). This decrease in HCV RNA level was associated with a significant reduction in liver inflammation as demonstrated by a decrease in alanine aminotransferase levels (p<0.0001, figure 1B ) and in serum protein and liver mRNA levels of the inflammatory cytokine CXCL10 (p=0.0004 and p=0.0002, figure 1C, D, respectively) . Nineteen patients were sustained virological responders with no detectable HCV RNA at week 12 post therapy. One patient stopped treatment at week 8 due to IFN intolerance, one patient experienced a virological breakthrough at week 8, and one patient relapsed after the end of treatment.
NK cells express increased STAT1, pSTAT1 and TRAIL levels in HCV infection with further increase during QUAD therapy
NK cells express the IFNα/β receptor, but not the IFNλ receptor chain 1 24 and thus can be used to monitor immune activation by endogenous 5 6 and exogenous type I IFN. 6 21 Engagement of the IFNα/β receptor on NK cells results in Jak-STAT signalling, which includes STAT1 phosphorylation and increased transcription of ISGs. STAT1 and the cytotoxic effector molecule TRAIL are themselves ISGs and can therefore be used in addition to pSTAT1 to monitor NK cell activation by endogenous and exogenous IFNα.
Using multicolour flow cytometry, NK cells were identified as CD3-CD56+cells in the PBMC population by sequential gating on single cells, lymphocytes and CD14-CD19-live cells ( figure  2A) . As illustrated by representative dot plots (figure 2B, C) and data from all studied subjects (figure 3), the frequencies of STAT1+ and TRAIL+ NK cells were significantly higher in patients with HCV infection than in uninfected subjects ( p<0.0001 and p=0.037, respectively, figure 3A , B, left graphs). Likewise, the expression level (mean fluorescence intensity, MFI) of STAT1 and TRAIL per cell were significantly higher for NK cells of patients with HCV infection than of uninfected subjects ( p=0.0007 and p=0.022, respectively, figure 3A , B, right graphs), reflecting a response to HCV-induced endogenous IFNα. Importantly, all patients with HCV infection were studied at two time points in chronic HCV infection, that is, at a time point prior to therapy ('pre') and at day 0 of therapy with consistent results. Within the first 24 h of QUAD therapy, the percentage of STAT1+ and TRAIL+ NK cells ( p=0.0002 and p=0.004, respectively) and the expression level of these markers per NK cell ( p<0.0001 and p=0.0008, respectively) increased further ( figure 3A, B) . The frequency of pSTAT1+ NK cells and the pSTAT1 level per NK cell (representative dot plots shown in figure 2D ) increased simultaneously ( p<0.0001 and p<0.0001, respectively, figure 3C ), consistent with a response to the injected PegIFN. NK cell subset analysis revealed a differential response of CD56 dim and CD56 bright NK cells. While pSTAT1 expression was equal in CD56 dim and CD56 bright NK cells subsets, STAT1 expression was greater in the CD56 dim NK cell subset and TRAIL expression was greater in the CD56 bright subset (see online supplementary figures S1 and S2). All parameters remained increased during follow-up due to the weekly injection of PegIFN. These results indicate that NK cells are activated by both endogenous and exogenous type I IFN in HCV infection.
The first phase virological response correlates with the increase in STAT1 and TRAIL levels in NK cells during QUAD therapy Next, we asked whether the rapid decline in viremia at the start of QUAD therapy was associated with the change in NK cell phenotype. As seen in figure 4 , the log 10 decrease in HCV RNA level during the first 6 h of therapy correlated with the 24 h increase in STAT1 and TRAIL expression in NK cells in a linear regression ( p=0.04, R 2 =0.19 for STAT1 and p=0.04, R 2 =0.20 for TRAIL, figure 4A, B) . A stronger correlation was observed for the 24 h decrease in HCV RNA level and the increase in STAT1 and TRAIL expression during the same period (p=0.02, R 2 =0.24, respectively, figure 4C, D) .
The NK cell response to PegIFN is greater during QUAD therapy than during PegIFN/RBV therapy
To assess the effect of the rapid DCV/ASV-mediated decrease in viremia on the NK cell response to the injected PegIFN, we performed a paired analysis of the early NK cell response of seven patients during QUAD therapy and during previous PegIFN/ RBV therapy. While QUAD therapy resulted in an average 3 log 10 decrease in HCV viremia within 24 h, the previous course of PegIFN/RBV therapy did not significantly reduce HCV viremia in these patients ( figure 5A ). For each patient, cryopreserved PBMC from both treatment courses were thawed at the same time and tested for STAT1, pSTAT1 and TRAIL expression. As shown in figure 5B , C, the 24 h increase in STAT1 and pSTAT1 expression in NK cells in response to the first dose of injected PegIFN was significantly greater during QUAD therapy than during PegIFN/RBV therapy. This was consistent with a trend towards a greater increase in the frequency of pSTAT1+ NK cells during the first 24 h of QUAD therapy than during PegIFN/RBV therapy ( figure 5D ). Likewise, the increase in TRAIL expression level per NK cell and the increase in the percentage of TRAIL+ NK cells were significantly greater in response to the first dose of PegIFN during QUAD therapy than during PegIFN/RBV therapy ( figure 6A, B) . Because the smaller CD56 bright NK cell subpopulation expresses higher TRAIL levels than the bulk NK cell population (see online supplementary figure S2B compared with figure 3B), we confirmed that the differential increase in TRAIL expression in both treatment courses extended to CD56 bright NK cell subset ( figure 6C, D) . These results demonstrate that the addition of DCV and ASV to the PegIFN/RBV treatment regimen improves the NK cell response to the first dose of injected PegIFN.
Successful QUAD therapy normalises the IFNα-induced NK cell response for at least 24 weeks after the end of therapy To evaluate whether successful QUAD therapy results in longterm improvement of NK cell function in response to IFNα, we studied NK cells prior to and week 24 after the end of QUAD therapy. Using cell surface expression of the degranulation marker CD107a as a readout for NK cell cytotoxicity, we showed that the ex vivo frequency of CD107a+ NK cells decreased significantly from pretreatment to week 24 after the end of QUAD therapy ( figure 7A, left graph) , and that this was associated with a concomitant increase in the NK cells' ability to respond to in vitro stimulation with IFNα (figure 7A, right graph). These results extended to the CD56 dim NK cell population (figure 7B), which is regarded as more cytotoxic than the CD56 bright population. 25 Moreover, while total NK cells and CD56 dim NK cells from patients with HCV prior to QUAD therapy had a significantly lower ability to degranulate in response to IFNα than those of healthy controls, their response was completely normalised at week 24 after the end of QUAD therapy ( figure 7A, B) . In fact, there was a direct correlation between the decrease in the frequency of CD107a+ CD56 dim NK cells during the course of QUAD therapy and their responsiveness to in vitro stimulation with IFNα in a linear regression analysis ( figure 7C) . Collectively, these results show that the early DAA-mediated decrease in viremia at the beginning of QUAD therapy improves the NK cell response to the first dose of injected PegIFN and that complete HCV clearance over the course of therapy results in long-term improvement of NK cell function in response to IFNα.
IFN-free therapy with DCV/ASV improves IFNα-signalling in NK cells
As a validation cohort, we studied nine PegIFN/RBV nonresponders who were treated with an IFN-free regimen of DCV/ ASV. Similar to the course of viremia during QUAD therapy figure 7 , because the sole pretreatment blood sample of this patient that was available for the CD107 assays was obtained more than 2 years prior to QUAD therapy. IFN, interferon; NK, natural killer; QUAD, quadruple.
(figure 5A), viremia decreased by more than 2 log 10 within 24 h of IFN-free DCV/ASV therapy (figure 8A) and was undetectable by week 2-4 of therapy. 15 While NK cells of the QUAD cohort were exposed to PegIFNα in vivo, NK cells of the IFN-free cohort were subjected to in vitro stimulation with recombinant IFNα. The fold-increase in the frequency and MFI of pSTAT1+ NK cells after in vitro stimulation with IFNα was used as a readout for IFN responsiveness of NK cells. As shown in figure 8B -E, the DAA-mediated decrease in HCV viremia during successful DAA therapy improved the pSTAT1 response of NK cells to in vitro stimulation with recombinant IFNα. This improved IFN responsiveness was observed within the first 24 h of treatment initiation (figure 8B, C) and was more prominent when treatment start and end dates were compared ( figure 8D, E) .
IFN-free therapy with DCV/ASV improves the effector response of NK cells
The concept of improved IFN responsiveness was further validated by determining the IFN-sensitivity of NK cells before and after successful DCV/ASV therapy in a titration experiment using IFN-induced expression of the cytotoxic molecule TRAIL as a readout. As shown in figure 9, PBMC were in vitro stimulated with the indicated concentration of IFNα and the percentage of TRAIL+ cells in the CD56 bright NK cell population was determined. Because TRAIL expression is greater in the CD56 bright than in the CD56 dim NK cell subset (see online supplementary figures S1 and S2) and to be consistent with the literature, [26] [27] [28] we gated on CD56 bright NK cells in this analysis. For each of the indicated patients ( patient numbers refer to table 1), the EC50, that is, the IFNα concentration that stimulated 50% of the maximal TRAIL response of CD56 bright NK cells, decreased significantly during the course of DCV/ASV therapy (p=0.031 comparing the mean EC50 values prior to and at the end of successful DCV/ASV therapy). These results indicate that HCV clearance improves the NK cell sensitivity to IFNα.
DISCUSSION
The development of potent DAAs has opened a new era of HCV treatment and cure. 29 It has also offered a unique opportunity to investigate the homeostasis of the intrahepatic innate immune system. IFNα is an important part of the intrahepatic immune system because it stimulates antiviral effector functions of infected hepatocytes via the induction of ISGs 30 and it recruits and activates innate immune cells such as NK cells. 20 However, both clinical and experimental data demonstrate that HCV persists despite increased ISG expression. 31 32 The presence of high ISG levels in the liver and a highly activated NK cell phenotype in the blood [7] [8] [9] are associated with a reduced response to IFN-based therapy. 3 Because non-responsiveness to IFN-based therapy is also associated with an unfavourable host genotype, [10] [11] [12] it is unknown whether IFN responsiveness can be modulated.
The current study demonstrates that IFN-responsiveness is not solely determined by genetics. It was prompted by our recent demonstration that patients with a less than 2 log 10 firstphase HCV RNA decline during PegIFN/RBV therapy exhibit a significantly lower increase in NK cell pSTAT1 induction in response to PegIFN than patients with a greater than 2 log 10 first-phase HCV RNA decline. 6 Remarkably, NK cells of the slow virological responders retained their in vitro responsiveness to IFNα in that study. 6 These results suggested that the suboptimal PegIFN response was not due to an irreversible NK cell intrinsic or genetic factor, but due to a factor that was present in vivo but not in the in vitro experiment. We now show that this factor is the virus itself because rapid DAA-mediated inhibition of viral replication improves the response to PegIFN. Importantly, while all patients in the study by Edlich et al responded to PegIFN/RBV therapy (although with different viral kinetics), the current study was conducted in previous PegIFN/ RBV non-responders. We show here that a reduction in HCV viremia improves the IFNα response of patients even if they have an unfavourable genetic background and provide a mechanistic rationale for treatment combination of DAA with PegIFN. This is consistent with a recent study on mathematical modelling, which suggested that DAAs may reset the altered steady state of the intrahepatic IFN signalling network in the chronically HCV-infected liver. 33 As a readout for IFN responsiveness, we quantified the frequency of pSTAT1, STAT1 and TRAIL+ NK cells and the respective expression level of these markers. Phosphorylation of STAT1 represents one of the earliest events after engagement of the IFNα/β receptor. Of note, NK cells do not express the IFNλ receptor chain 1, 24 which excludes the possibility that type III IFNs directly contribute to this effect. pSTAT1 forms heterodimers with pSTAT2, which then interact with the IFN regulatory factor 9 to form the IFN-stimulated gene factor 3 transcription complex. Nuclear translocation and binding of this complex to the IFN-stimulated response element induces the transcription of ISGs. TRAIL is one of the most responsive ISGs in human NK cells as shown by transcriptional profiling of IFNα-stimulated NK cells from healthy controls 26 and is also a relevant effector molecule against HCV. 26 Studying NK cell degranulation as a readout for cytotoxicity we also confirmed that successful QUAD therapy resulted in long-term improvement of NK cell function in response to IFNα.
While an NK cell-mediated antiviral effect has been shown in co-cultures with hepatoma cells that were either infected with HCV 34 35 or harboured subgenomic HCV replicons, 35 36 it is important that we are not concluding that the antiviral effect of PegIFN-based therapy is mediated by NK cells. Rather NK cells are used as a readout for IFN responsiveness in this study. Intrahepatic ISG induction in the early phase of IFN-based therapy has been validated as an indicator of IFN responsiveness and predictor of treatment response. 3 We argue that there are parallels between IFN responsiveness (ISG induction) of the liver as described by Dill et al 37 and IFN responsiveness ( pSTAT1, STAT1 and TRAIL induction) of NK cells as described in this study. The high response rate in our cohort requires PegIFN/RBV and is not due to DCV/ASV alone, because patients with HCV genotype 1a infection have a low SVR rate when treated with an IFN-free DCV/ASV regimen. 17 18 Collectively, the results may explain the benefit of combining PegIFN with DAA/RBV therapy in some patient populations as shown in the BOSON study, 2 and may also provide a rationale for clinical trials of a brief period of DAA therapy followed by PegIFN/RBV therapy to reduce the overall costs of treatment in middle-income and low-income countries. Whether improved NK cell responsiveness to IFN may also be relevant for immune surveillance and prevention of viral relapse is an interesting area for future research.
